首页> 美国卫生研究院文献>Arthritis Research >Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort
【2h】

Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort

机译:英国类风湿关节炎患者中C反应蛋白单倍型与血清C反应蛋白水平和对抗肿瘤坏死因子治疗的反应的相关性:类风湿关节炎遗传学和基因组学研究的生物学结果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

IntroductionIn many European countries, restrictions exist around the prescription of anti-tumor necrosis factor (anti-TNF) treatments for rheumatoid arthritis (RA). Eligibility and response to treatment is assessed by using the disease activity score 28 (DAS28) algorithm, which incorporates one of two inflammatory markers, erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Although DAS28-CRP provides a more reliable measure of disease activity, functional variants exist within the CRP gene that affect basal CRP production.Therefore, we aimed to determine the relation between functional genetic variants at the CRP gene locus and levels of serum CRP in RA patients, and whether these variants, alone or in combination, are correlated with DAS28-CRP and change in DAS28-CRP after anti-TNF treatment.
机译:简介在许多欧洲国家/地区,针对类风湿关节炎(RA)的抗肿瘤坏死因子(anti-TNF)治疗处方存在限制。通过使用疾病活动评分28(DAS28)算法评估合格性和对治疗的反应,该算法结合了两种炎症标记之一,即红细胞沉降率(ESR)或C反应蛋白(CRP)。尽管DAS28-CRP提供了更可靠的疾病活动度量,但CRP基因内存在影响基础CRP产生的功能变异,因此,我们旨在确定CRP基因位点的功能遗传变异与RA中血清CRP水平之间的关系。患者,以及这些变体(单独还是组合使用)与DAS28-CRP和抗TNF治疗后DAS28-CRP的变化有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号